104 related articles for article (PubMed ID: 22943612)
1. When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies.
Arnold ME; Lacreta F
Bioanalysis; 2012 Aug; 4(15):1831-4. PubMed ID: 22943612
[No Abstract] [Full Text] [Related]
2. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
Bae SK; Shon JH
Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
[TBL] [Abstract][Full Text] [Related]
3. Applications of accelerator MS in pediatric drug evaluation.
Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
[TBL] [Abstract][Full Text] [Related]
4. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
Sarapa N; Hsyu PH; Lappin G; Garner RC
J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
[TBL] [Abstract][Full Text] [Related]
5. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
Ings RM
Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
[TBL] [Abstract][Full Text] [Related]
6. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
[TBL] [Abstract][Full Text] [Related]
7. The application of human phase 0 microdosing trials: A systematic review and perspectives.
Svendsen P; El-Galaly TC; Dybkær K; Bøgsted M; Laursen MB; Schmitz A; Jensen P; Johnsen HE
Leuk Lymphoma; 2016; 57(6):1281-90. PubMed ID: 26428262
[TBL] [Abstract][Full Text] [Related]
8. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Gu H; Wang J; Aubry AF; Jiang H; Zeng J; Easter J; Wang JS; Dockens R; Bifano M; Burrell R; Arnold ME
Anal Chem; 2012 Jun; 84(11):4844-50. PubMed ID: 22540405
[TBL] [Abstract][Full Text] [Related]
9. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
[TBL] [Abstract][Full Text] [Related]
10. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
11. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
Lappin G; Stevens L
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
[TBL] [Abstract][Full Text] [Related]
12. Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
Muller PY
Adv Drug Deliv Rev; 2011 Jun; 63(7):511-7. PubMed ID: 21034787
[TBL] [Abstract][Full Text] [Related]
13. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
[TBL] [Abstract][Full Text] [Related]
14. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
[TBL] [Abstract][Full Text] [Related]
15. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
16. Microdosing for early biokinetic studies in humans.
Stenström K; Sydoff M; Mattsson S
Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
[TBL] [Abstract][Full Text] [Related]
17. Could traditional mass-balance studies in the 'twilight zone' be improved by means of accelerator MS measurements?
Svensson LD
Bioanalysis; 2012 Aug; 4(15):1835-7. PubMed ID: 22943613
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC-DAD-MSn.
Zhao YY; Su Q; Cheng XL; Tan XJ; Bai X; Lin RC
Bioanalysis; 2012 Mar; 4(6):713-23. PubMed ID: 22452262
[TBL] [Abstract][Full Text] [Related]
19. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
[TBL] [Abstract][Full Text] [Related]
20. Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS: application of pharmacokinetic study in rats.
Ren HC; Sun JG; Wang GJ; A JY; Xie HT; Zha WB; Yan B; Sun FZ; Hao HP; Gu SH; Sheng LS; Shao F; Shi J; Zhou F
J Pharm Biomed Anal; 2008 Dec; 48(5):1476-80. PubMed ID: 19022601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
